stoxline Quote Chart Rank Option Currency Glossary
  
Kala Pharmaceuticals, Inc. (KALA)
6.99  -0.05 (-0.71%)    11-01 16:00
Open: 7.02
High: 7.1
Volume: 12,289
  
Pre. Close: 7.04
Low: 6.8792
Market Cap: 32(M)
Technical analysis
2024-11-01 4:45:54 PM
Short term     
Mid term     
Targets 6-month :  8.45 1-year :  9.87
Resists First :  7.23 Second :  8.45
Pivot price 6.09
Supports First :  5.82 Second :  4.94
MAs MA(5) :  7.05 MA(20) :  5.88
MA(100) :  6.1 MA(250) :  6.64
MACD MACD :  0.3 Signal :  0.2
%K %D K(14,3) :  87.7 D(3) :  90.4
RSI RSI(14): 70.2
52-week High :  10.97 Low :  4.21
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ KALA ] has closed below upper band by 23.2%. Bollinger Bands are 126.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 7.11 - 7.14 7.14 - 7.18
Low: 6.78 - 6.82 6.82 - 6.86
Close: 6.91 - 6.98 6.98 - 7.05
Company Description

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

Headline News

Tue, 29 Oct 2024
Persistent Corneal Epithelial Defects Pipeline 2024: Clinical - openPR

Sun, 27 Oct 2024
Long Term Trading Analysis for (KALA) - Stock Traders Daily

Wed, 09 Oct 2024
Limbal Stem Cells Deficiency Market Enhanced Profitability, - openPR

Sat, 21 Sep 2024
2024 Vision: Dry Eye Syndrome Market Innovation and Growth - WhaTech

Thu, 27 Jun 2024
KALA BIO Announces $12,500,000 Private Placement - Yahoo Finance

Wed, 29 May 2024
KALA BIO to Present at Jefferies Global Healthcare Conference - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 5 (M)
Shares Float 3 (M)
Held by Insiders 5.1 (%)
Held by Institutions 47.7 (%)
Shares Short 29 (K)
Shares Short P.Month 22 (K)
Stock Financials
EPS -13.53
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.98
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -40.3 %
Return on Equity (ttm) -248.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -7.48
Qtrly Earnings Growth 0 %
Operating Cash Flow -31 (M)
Levered Free Cash Flow -21 (M)
Stock Valuations
PE Ratio -0.52
PEG Ratio -0.1
Price to Book value 2.34
Price to Sales 0
Price to Cash Flow -1.25
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android